OctreoPharm’s OPS202 receives FDA orphan drug status for neuroendocrine tumors
Currently, OPS202 is evaluated in Phase I/II clinical trials and is based on a new next generation antagonistic somatostatin analog with improved receptor binding to sst2. The company